Cells: Hemostemix ACP-01 and NCP-01 Provides the Scientific Basis for Improving the Longevity and Signal Uptake of Brain Computer Implants

Hemostemix (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) (“Hemostemix” or the “Company“) is excited to highlight a groundbreaking research article published in Cells on June?29,?2025, by Dr. Fraser C. Henderson Sr. and Ms. Kelly?Tuchman, exploring how a combination of the patient’s own ACP-01 and NCP-01 (autologous blood-derived cell precursors) may support the long-term performance of brain-computer interfaces (BCIs).